These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15579085)

  • 1. Anti-HIV drug development--an overview.
    Pereira CF; Paridaen JT
    Curr Pharm Des; 2004; 10(32):4005-37. PubMed ID: 15579085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel compounds in preclinical/early clinical development for the treatment of HIV infections.
    De Clercq E
    Rev Med Virol; 2000; 10(4):255-77. PubMed ID: 10891872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 drug resistance: can we overcome?
    Brenner BG; Turner D; Wainberg MA
    Expert Opin Biol Ther; 2002 Oct; 2(7):751-61. PubMed ID: 12387674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
    Garbelli A; Riva V; Crespan E; Maga G
    Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors.
    Imamichi T
    Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recent progress in anti-HIM-1 research].
    Baba M
    Uirusu; 2004 Jun; 54(1):59-66. PubMed ID: 15449905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.
    Menéndez-Arias L
    Antiviral Res; 2013 Apr; 98(1):93-120. PubMed ID: 23403210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The newest developments in anti-HIV-1 drugs].
    Zhang XQ
    Yao Xue Xue Bao; 2010 Feb; 45(2):194-204. PubMed ID: 21351429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs for old.
    Winston A; Stebbing J
    J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in anti-HIV chemotherapy.
    De Clercq E
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule inhibitor of HIV-1 nuclear import suppresses HIV-1 replication in human lymphoid tissue ex vivo: a potential addition to current anti-HIV drug repertoire.
    Glushakova S; Dubrovsky L; Grivel J; Haffar O; Bukrinsky M
    Antiviral Res; 2000 Aug; 47(2):89-95. PubMed ID: 10996396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
    Sierra-Aragón S; Walter H
    Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antiretroviral agents: looking beyond protease and reverse transcriptase.
    Miller MD; Hazuda DJ
    Curr Opin Microbiol; 2001 Oct; 4(5):535-9. PubMed ID: 11587929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy.
    Hauber I; Bevec D; Heukeshoven J; Krätzer F; Horn F; Choidas A; Harrer T; Hauber J
    J Clin Invest; 2005 Jan; 115(1):76-85. PubMed ID: 15630446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Virostatics" as a potential new class of HIV drugs.
    Kelly LM; Lisziewicz J; Lori F
    Curr Pharm Des; 2004; 10(32):4103-20. PubMed ID: 15579091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbial Natural Product Alternariol 5-O-Methyl Ether Inhibits HIV-1 Integration by Blocking Nuclear Import of the Pre-Integration Complex.
    Ding J; Zhao J; Yang Z; Ma L; Mi Z; Wu Y; Guo J; Zhou J; Li X; Guo Y; Peng Z; Wei T; Yu H; Zhang L; Ge M; Cen S
    Viruses; 2017 May; 9(5):. PubMed ID: 28489061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.